Compare Alcon AG (ALC) vs Thomson Reuters Corp (TRI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alcon AG vs Thomson Reuters Corp — how do they compare? Alcon AG trades at $66.03 (market cap $32.52B), while Thomson Reuters Corp trades at $97.35 (market cap $41.59B). The key difference: Thomson Reuters Corp is the larger of the two by market cap, and Thomson Reuters Corp pays the higher dividend (2.74%). Which is the better fit depends on your goals.
| ALC | TRI | |
|---|---|---|
Market Cap | $32.52B | $41.59B |
Sector | Health | Industrials |
52-Week High | $87.18 | $173.48 |
52-Week Low | $62.02 | $76.55 |
Enterprise Value | $36.36B | $44.20B |
Dividend Yield | 0.54% | 2.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.03, down 3.51% on the day, with a bearish technical signal from moving averages but bullish oscillators. The company reported Q2 2026 EPS of $0.84, beating estimates, and raised its 2026 profit outlook. Revenue grew to $10.40 billion in 2025, though net income margin dipped to 9.42%. Analyst consensus is bullish with a $85.85 price target, and recent news highlights product launches and tariff relief.
The stock offers upside to analyst targets but faces risks from competition and margin pressure. Positive earnings beats and institutional interest from investors like Bill Ackman support growth prospects, yet valuation multiples like a P/E of 50.8 require sustained profit expansion to justify current levels.
Thomson Reuters (TRI) trades at $97.35, up 0.38% in the past 24 hours, with a bearish technical signal but strong fundamentals including a 21.22% net income margin and 8% organic revenue growth in Q2 2026. Recent news highlights AI expansion with the launch of its proprietary Thomson-1 LLM and a cybersecurity incident affecting its C-Track platform. The stock is near its pivot point of $97, with support at $95 and resistance at $98.
The outlook is mixed: analyst consensus is bullish with a $113 price target, but technical indicators suggest near-term weakness. Risks include cybersecurity vulnerabilities and margin pressure, while opportunities lie in AI-driven growth and recurring revenue strength. Investors should weigh robust profitability against market sentiment and operational risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About Thomson Reuters Corp
Thomson Reuters is the result of the $17.6 billion megamerger of Canada's Thomson and the United Kingdom's Reuters Group in 2008 and the 2018 carve-out of its finance and risk business, Refinitiv, in which it holds a 45% stake. In 2019, the company agreed to exchange its 45% stake in Refinitiv for a 15% stake in LSE, which closed in early 2021. Since the divestiture, the company is more concentrated on selling its flagship legal data and software, Westlaw, and its tax accounting software, Onesource. Reuters sees roughly 80% of revenue and 70% of expenses attributed to the United States, while the remainder (largely through the global print and Reuters News segments) is distributed across Latin America, Europe, the Middle East, Africa, and Asia-Pacific.
Read more on TRI →
